A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

• Status: Not yet recruiting
• Trial end date: 2027-05-04
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biogen

Criteria

Key Inclusion Criteria:

• The participant must have confirmed amyloid beta pathology by cerebrospinal fluid (CSF) or amyloid PET

• Must have a history of subjective memory decline with gradual onset and slow progression over the 6 months before Screening, confirmed by study partner

• The participant must have 1 informant/care partner who, in the Investigator's opinion, has frequent and sufficient contact with the participant (at least 10 hours/week in person or by phone) as to be able to provide accurate information about the participant's cognitive and functional abilities over time

• Must meet all of the following clinical criteria for MCI due to Alzheimer's disease or mild Alzheimer's disease according to National Institute on Aging and Alzheimer's Association (NIA-AA) criteria

1. Have an MMSE score between 22 and 30 inclusive

2. Have a CDR memory score >0.5

3. Have a Clinical Dementia Rating Scale Global Score (CDR-GS) of 0.5 or 1.0

4. Have a Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score of 85 or lower indicative of objective cognitive impairment

• Apart from a clinical diagnosis of early Alzheimer's disease, the participant must be in good health as determined by the Investigator based on medical history and screening assessments

• Must consent to apolipoprotein E (ApoE) genotyping. (Note: Participants are not required to be ApoE ε4 carriers)

Key Exclusion Criteria:

• Any uncontrolled medical or neurological/neurodegenerative condition (other than Alzheimer's disease) that, in the opinion of the Investigator, might be a contributing cause of the participant's cognitive impairment

• Clinically significant and/or unstable psychiatric illness within 6 months prior to Screening

• Transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening

• History of severe allergic or anaphylactic reactions or of hypersensitivity to any of the inactive ingredients in the drug product

• Participation in any study with purported disease-modifying effect in Alzheimer's disease within 12 months prior to Screening unless documentation of receipt of placebo is available

• Current use or previous use of medications with a purported disease-modifying effect in Alzheimer's disease, outside of investigational studies

• Use of any medications that, in the opinion of the Investigator, may contribute to cognitive impairment, put the participant at higher risk for AEs, or impair the participant's ability to perform cognitive testing or complete study procedures

• Use of any investigational drug

• Prior exposure to aducanumab either commercially or by participation in a previous study with aducanumab. (Participants are eligible if they did not receive active aducanumab.)

• A negative PET scan result with any amyloid-targeting ligand within 12 months prior to Screening

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply